Duodenal Ulcer Treatment Market To Reach $5.54 Billion By 2030

Duodenal Ulcer Treatment Market Growth & Trends

The global duodenal ulcer treatment market size is anticipated to reach USD 5.54 billion by 2030, growing at a CAGR of 3.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of elements focused on the management and treatment of duodenal ulcers, which are sores that occur in the lining of the duodenum.

Pharmacological treatments are crucial to the duodenal ulcer treatment market. These medications include proton pump inhibitors (PPIs), histamine receptor antagonists (H2RAs), and antibiotics targeting Helicobacter pylori infections, mucosal protectants, and antacids. These medications reduce gastric acid production, eradicate bacterial pathogens, enhance mucosal defense, or neutralize stomach acid. This therapeutic approach alleviates bloating, abdominal pain, and discomfort while accelerating ulcer healing.

The market is experiencing significant growth due to the incorporation of digital health solutions such as mobile apps, telemedicine platforms, and remote monitoring tools. These technologies enable personalized treatment management, real-time symptom tracking, and enhanced patient engagement. Additionally, artificial intelligence (AI) algorithms are being employed to analyze large datasets, which improves treatment outcomes and facilitates early detection of ulcer issues.

 Request a free sample copy or view report summary: Duodenal Ulcer Treatment Market Report

Duodenal Ulcer Treatment Market Report Highlights

• Based on treatment, the proton pump inhibitors dominated the market with the largest revenue share of 52.3% in 2023 due to their superior effectiveness in managing and healing duodenal ulcers.The widespread use of PPIs is driven by their favorable safety profile and high tolerability. They are available in various formulations, including extended-release options, which enhance patient compliance and convenience.

• Based on route of administration, the oral segment dominated the market with the largest revenue share of 78.44% in 2023. Oral formulations are generally more cost-effective than injectable or intravenous options, contributing to their widespread use. Their extensive market presence and proven efficacy reinforce their leading revenue share in the treatment market.

• Based on distribution channel, the retail pharmacies segment dominated the market with the largest revenue share of 57.45% in 2023. Retail pharmacies offer patients immediate access to medications without needing hospital or specialist visits, enhancing convenience and adherence. Their established distribution networks and customer service also facilitate efficient medication management and refill processes, further driving revenue in this channel.

• Based on region, the North America region dominated the market with a significant share of 39.54% in 2023. This is driven by continuous innovation and extensive healthcare infrastructure. Innovations include the development of novel drug formulations and delivery systems aimed at improving patient compliance and treatment efficacy.

Duodenal Ulcer Treatment Market Segmentation

Grand View Research has segmented the global duodenal ulcer treatment market based on the treatment, route of administration,distribution channel, and region:

Duodenal Ulcer Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Proton Pump Inhibitors

• H2 Antagonists

• Antibiotics

• Other

Duodenal Ulcer Treatment Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Parenteral

Duodenal Ulcer Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Retail Pharmacies

• Hospital Pharmacies

• Other

Duodenal Ulcer Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Duodenal Ulcer Treatment Market

• GSK plc.

• Pfizer

• Abbott

• Merck KGaA

• NIHON GENERIC Co., Ltd.

• Novartis AG

• Bristol-Myers Squibb Company

• AstraZeneca

• Takeda Pharmaceutical Company Limited

• Eisai Co., Ltd.